BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8916146)

  • 1. Expression of apoptosis, proliferating cell nuclear antigen, and apoptosis-related antigens (bcl-2, c-myc, Fas, Lewis(y) and p53) in human cholangiocarcinomas and hepatocellular carcinomas.
    Terada T; Nakanuma Y
    Pathol Int; 1996 Oct; 46(10):764-70. PubMed ID: 8916146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of apoptosis and expression of apoptosis-related proteins during human intrahepatic bile duct development.
    Terada T; Nakanuma Y
    Am J Pathol; 1995 Jan; 146(1):67-74. PubMed ID: 7531950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Regulation of p53 and bcl-2 proteins to apoptosis and cell proliferation in liver cirrhosis and hepatocellular carcinoma].
    Feng D; Zheng H; Shen M; Cheng R; Yan Y
    Hunan Yi Ke Da Xue Xue Bao; 1999; 24(4):325-8. PubMed ID: 12080637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High levels of BCL-2 messenger RNA detected by in situ hybridization in human hepatocellular and cholangiocellular carcinomas.
    Fiorentino M; D'Errico A; Altimari A; Barozzi C; Grigioni WF
    Diagn Mol Pathol; 1999 Dec; 8(4):189-94. PubMed ID: 10617275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 but not bcl-2 is expressed by most cholangiocarcinomas: a study of 28 cases.
    Arora DS; Ramsdale J; Lodge JP; Wyatt JI
    Histopathology; 1999 Jun; 34(6):497-501. PubMed ID: 10383693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human germinal center B cells express the apoptosis-inducing genes Fas, c-myc, P53, and Bax but not the survival gene bcl-2.
    Martinez-Valdez H; Guret C; de Bouteiller O; Fugier I; Banchereau J; Liu YJ
    J Exp Med; 1996 Mar; 183(3):971-7. PubMed ID: 8642300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of antigens related to apoptosis and cell proliferation in chronic nonsuppurative destructive cholangitis in primary biliary cirrhosis.
    Kuroki T; Seki S; Kawakita N; Nakatani K; Hisa T; Kitada T; Sakaguchi H
    Virchows Arch; 1996 Oct; 429(2-3):119-29. PubMed ID: 8917713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative immunohistochemical expression of p63 in human cholangiocarcinoma and hepatocellular carcinoma.
    Ramalho FS; Ramalho LN; Della Porta L; Zucoloto S
    J Gastroenterol Hepatol; 2006 Aug; 21(8):1276-80. PubMed ID: 16872309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulators of apoptosis in cholangiocarcinoma.
    Jhala NC; Vickers SM; Argani P; McDonald JM
    Arch Pathol Lab Med; 2005 Apr; 129(4):481-6. PubMed ID: 15794670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of blood group-related antigens in cholangiocarcinoma in relation to non-neoplastic bile ducts.
    Minato H; Nakanuma Y; Terada T
    Histopathology; 1996 May; 28(5):411-9. PubMed ID: 8735716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of p53 on apoptosis and proliferation of hepatocellular carcinoma cells treated with transcatheter arterial chemoembolization.
    Xiao EH; Li JQ; Huang JF
    World J Gastroenterol; 2004 Jan; 10(2):190-4. PubMed ID: 14716820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of Lewis blood group antigens in cancerous and non-cancerous liver.
    Kanai T; Hirohashi S; Upton MP; Ino Y; Shimosato Y
    Jpn J Cancer Res; 1987 Sep; 78(9):968-76. PubMed ID: 2822639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biliary dysplasia, cell proliferation and nuclear DNA-fragmentation in primary sclerosing cholangitis with and without cholangiocarcinoma.
    Bergquist A; Glaumann H; Stål P; Wang GS; Broomé U
    J Intern Med; 2001 Jan; 249(1):69-75. PubMed ID: 11168786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Overexpression of c-myc and p53 gene in human hepato-cellular carcinoma--a study with immunohistochemistry and in situ hybridization].
    Yang S; Wang M; You W
    Zhonghua Zhong Liu Za Zhi; 1995 Nov; 17(6):415-7. PubMed ID: 8697990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imbalance between cell proliferation and cellular DNA fragmentation in hepatocellular carcinoma.
    Wu PC; Lau VK; Fang JW; Lai VC; Lai CL; Lau JY
    Liver; 1999 Oct; 19(5):444-51. PubMed ID: 10533805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors.
    Terada T; Okada Y; Nakanuma Y
    Hepatology; 1996 Jun; 23(6):1341-4. PubMed ID: 8675149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of both hepatocellular carcinoma and cholangiocarcinoma phenotypes in hepatocellular carcinoma and cholangiocarcinoma components in combined hepatocellular and cholangiocarcinoma.
    Itoyama M; Hata M; Yamanegi K; Yamada N; Ohyama H; Hirano H; Terada N; Nakasho K
    Med Mol Morphol; 2012 Dec; 45(1):7-13. PubMed ID: 22431178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical detection of bcl-2 protein in normal and pathological human liver.
    Charlotte F; L'Herminé A; Martin N; Geleyn Y; Nollet M; Gaulard P; Zafrani ES
    Am J Pathol; 1994 Mar; 144(3):460-5. PubMed ID: 8129031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of p53 in adenocarcinoma of the gallbladder and bile ducts.
    Washington K; Gottfried MR
    Liver; 1996 Apr; 16(2):99-104. PubMed ID: 8740842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
    Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
    J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.